5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Pipeline Review, H2 2016

Published: Sep, 2016 | Pages: 87 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Pipeline Review, H2 2016

Summary

Global Markets Direct's, '5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Pipeline Review, H2 2016', provides in depth analysis on 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) targeted pipeline therapeutics. 

The report provides comprehensive information on the 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: 
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) 
- The report reviews 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) targeted therapeutics and enlists all their major and minor projects 
- The report assesses 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) 
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) Overview 9
Therapeutics Development 10
5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Products under Development by Stage of Development 10
5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Products under Development by Therapy Area 11
5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Products under Development by Indication 12
5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Pipeline Products Glance 14
Late Stage Products 14
Early Stage Products 15
Unknown Stage Products 16
5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Products under Development by Companies 17
5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Products under Development by Universities/Institutes 21
5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Therapeutics Assessment 23
Assessment by Monotherapy/Combination Products 23
Assessment by Mechanism of Action 24
Assessment by Route of Administration 25
Assessment by Molecule Type 26
5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Companies Involved in Therapeutics Development 27
Adamed Sp. z o.o. 27
Avineuro Pharmaceuticals, Inc. 28
Axovant Sciences Ltd. 29
Biotie Therapies Corp. 30
Celon Pharma Sp. z o.o. 31
Galenea Corp. 32
H. Lundbeck A/S 33
Reviva Pharmaceuticals Inc. 34
Suven Life Sciences Ltd. 35
Teva Pharmaceutical Industries Ltd. 36
5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Drug Profiles 37
ADN-1184 - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
ADN-2013 - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
ADN-3662 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
AV-3208 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
AVN-0189 - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
AVN-101 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
AVN-211 - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
AVN-3085 - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
AVN-3205 - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
AVN-322 - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
idalopirdine - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
intepirdine - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
landipirdine - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
LuAF-35700 - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
RP-5063 - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
Small Molecule 1 to Antagonize 5-HT6 Receptor for CNS Disorders - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
Small Molecule 2 to Antagonize 5-HT6 for CNS Disorders - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
Small Molecules to Antagonize 5-HT 6 and 5-HT2A for Behavioral and Psychological Symptoms of Dementia - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
Small Molecules to Antagonize 5-HT6 for Alzheimer's Disease - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
Small Molecules to Antagonize 5-HT6 Receptor for Central Nervous System Disorders - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
Small Molecules to Antagonize 5-HT6 Receptors for Cognitive Impairment - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
Small Molecules to Target 5-HT2C and 5-HT6 Receptor for Schizophrenia - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
SUVN-501 - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
SUVN-502 - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
SUVN-507 - Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
SUVN-512 - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Dormant Projects 70
5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Discontinued Products 75
5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Featured News & Press Releases 76
Jul 07, 2016: Idalopirdine granted Fast Track Designation by U.S. Food and Drug Administration (FDA) 76
May 19, 2016: Reviva Pharmaceuticals Presented RP5063 Preclinical Efficacy Results for Pulmonary Arterial Hypertension at the American Thoracic Society Conference 2016 76
Apr 21, 2016: FAU site for first US clinical trial for Lewy Body dementia 77
Apr 11, 2016: Lundbeck to Present Data on Idalopirdine at American Academy of Neurology 78
Mar 11, 2016: Lundbeck starts clinical phase III program with Lu AF35700 in patients with treatment resistant schizophrenia 78
Feb 09, 2016: Axovant Sciences Announces Launch Of First-In-Class Clinical Programs Of RVT-101 For Lewy Body Dementia 79
Dec 07, 2015: Suven Initiates Phase 2A trial of SUVN-502 in USA in Alzheimer's Disease 80
Oct 28, 2015: Axovant Sciences Announces RVT-101 Presentations At The Clinical Trials In Alzheimer's Disease Meeting 81
Oct 22, 2015: Reviva Pharmaceuticals Reports RP5063 Positive Efficacy Results for Memory Deficits 81
Oct 06, 2015: Axovant Sciences Announces Start Of Confirmatory Phase 3 MINDSET Study And Special Protocol Assessment Agreement With FDA 82
Jul 22, 2015: Axovant's RVT-101 Phase 2b Completer Analysis Demonstrates Statistically Significant Benefits in Cognition and Function Through 48 Weeks 82
Jul 01, 2015: Avineuro Completed Phase II Clinical Study Of AVN-211, A Selective 5-HT6 Receptor Antagonist 84
Jun 29, 2015: Axovant Sciences To Present RVT-101 Alzheimer's Disease Clinical Data At AAIC 2015 Meeting 84
Dec 23, 2014: Biotie Announces Start Of Syn120 Phase 2A Trial In Parkinson's Disease Dementia And Provides Outlook Update For Near Term Pipeline Events 85
Sep 08, 2014: Suven Life Sciences Provides Update On Its Molecule For Alzheimer's Disease 85
Appendix 86
Methodology 86
Coverage 86
Secondary Research 86
Primary Research 86
Expert Panel Validation 86
Contact Us 86
Disclaimer 87

List of Tables

Number of Products under Development for, H2 2016 10
Number of Products under Development by Therapy Area, H2 2016 11
Number of Products under Development by Indication, H2 2016 13
Comparative Analysis by Late Stage Development, H2 2016 14
Comparative Analysis by Early Stage Products, H2 2016 15
Comparative Analysis by Unknown Stage Development, H2 2016 16
Number of Products under Development by Companies, H2 2016 17
Products under Development by Companies, H2 2016 18
Products under Development by Companies, H2 2016 (Contd..1) 19
Products under Development by Companies, H2 2016 (Contd..2) 20
Number of Products under Investigation by Universities/Institutes, H2 2016 21
Products under Investigation by Universities/Institutes, H2 2016 22
Assessment by Monotherapy/Combination Products, H2 2016 23
Number of Products by Stage and Mechanism of Action, H2 2016 24
Number of Products by Stage and Route of Administration, H2 2016 25
Number of Products by Stage and Molecule Type, H2 2016 26
Pipeline by Adamed Sp. z o.o., H2 2016 27
Pipeline by Avineuro Pharmaceuticals, Inc., H2 2016 28
Pipeline by Axovant Sciences Ltd., H2 2016 29
Pipeline by Biotie Therapies Corp., H2 2016 30
Pipeline by Celon Pharma Sp. z o.o., H2 2016 31
Pipeline by Galenea Corp., H2 2016 32
Pipeline by H. Lundbeck A/S, H2 2016 33
Pipeline by Reviva Pharmaceuticals Inc., H2 2016 34
Pipeline by Suven Life Sciences Ltd., H2 2016 35
Pipeline by Teva Pharmaceutical Industries Ltd., H2 2016 36
Dormant Projects, H2 2016 70
Dormant Projects (Contd..1), H2 2016 71
Dormant Projects (Contd..2), H2 2016 72
Dormant Projects (Contd..3), H2 2016 73
Dormant Projects (Contd..4), H2 2016 74
Discontinued Products, H2 2016 75